Novartis' Gilenya fails in study for a type of MS

December 1, 2014 6:47 AM

6 0

Novartis' Gilenya fails in study for a type of MS

ZURICH (Reuters) - Novartis AG said on Monday its drug Gilenya failed to meet its main goal in a late-stage study as a treatment for primary progressive multiple sclerosis (PPMS).

Results of the Phase III trial involving 970 people found Gilenya, also known as fingolimod, did not show a significant difference to placebo on a combination of disability measures.

Read more

To category page

Loading...